A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia.

PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

March 31, 2013

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions

Purpura, Thrombocytopaenic, Idiopathic

Interventions

DRUG

Belimumab

10 mg /kg given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)

DRUG

Normal saline placebo

Placebo given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)